Magazine Article | September 1, 2020

5 Steps To Prepare For A Third-Party Drug Price Evaluation

Source: Life Science Leader

By Matt Sussman

Determining fair and reasonable drug prices in the U.S. has long been a source of debate. Unlike countries such as Australia and Canada, which have established health technology assessment (HTA) organizations, the U.S. has long lacked consistent, independent economic analysis to assess the value of new drugs.

While four U.S. value assessment frameworks have been created by clinical societies, including the American Heart Association, to inform physician and patient decisions, these frameworks tend to focus on one specific therapeutic area in support of treatment decision-making. As a result, there’s no predetermined way to evaluate the clinical and economic value for new medications that come to market.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: